What Tationil Treats: Main Uses and Benefits

Tationil (Reduced L-Glutathione) is commonly used to help with systemic imbalance in specific clinical situations. The therapeutic approach focuses on supporting organs and systems that are particularly vulnerable to increased physiological stress, and may provide support that helps ease the overall symptom burden associated with chronic injury. One key therapeutic domain is its role as an adjunctive agent.

The medication is considered relevant for addressing symptoms linked to organ-specific functional stress, such as elevated liver enzyme levels in chronic hepatic injury (e.g., NAFLD/MASLD). It is also applied in addressing the risk of peripheral neuropathy and related toxicities caused by certain highly reactive chemotherapy drugs. Furthermore, it is relevant in supportive protocols for neurodegenerative conditions like Parkinson’s disease. This assistance may help patients cope more steadily with symptom fluctuations.

“The supportive benefit helps improve day-to-day comfort during symptomatic periods.”

---

Quick Fact: Support for Symptoms Related to Systemic Imbalance

---

This section summarizes the official eligibility and non-eligibility information for Tationil (Glutathione) based on documented government regulatory sources.

Populations That Must Not Use Tationil

Classification	Population/Condition
Contraindicated	Individuals with known hypersensitivity or allergy to the active substance, glutathione, or any of the product's inactive ingredients.
Not Recommended	Women who are pregnant or are currently breastfeeding (due to a lack of sufficient reliable safety data).
Restriction	Patients with pre-existing asthma are advised to avoid the inhaled/nebulized formulation, as it may exacerbate respiratory symptoms.

Eligibility Constraints

The medicine is generally restricted to use in patients being treated for officially approved therapeutic indications. Regulatory bodies have issued advisories against the use of injectable glutathione for non-approved purposes, such as skin lightening, noting associated safety concerns.

Use in the pediatric population is not fully established in official labeling and is generally restricted to adults in the context of approved therapeutic uses. Any application of this medicine must be strictly guided by a qualified healthcare professional, adhering only to authorized uses and official product information.

Interactions with other medicines and products

This section summarizes the officially documented interaction profile for the parenteral formulation of Tationil (Reduced L-Glutathione), based on authoritative government regulatory documents.

Absence of Systemic Drug-Drug Interactions

Official prescribing information and regulatory labels for injectable Glutathione preparations do not formally list specific systemic drug-drug interactions (DDI) involving metabolic pathways (such as CYP enzymes) or drug transporters. Consequently, there are no official contraindications with other medicinal products based on risks associated with metabolic or pharmacodynamic interactions.

Chemical Compatibility Restrictions

The documented constraint associated with this product is procedural, focused on chemical compatibility during preparation and administration.

Interaction Type	Constraint Summary
Interacting Substance	Solutions containing Sodium Bisulfite
Restriction	Must not be mixed or co-administered in the same intravenous line or solution

This requirement stems from documented chemical interference between the active ingredient and the preservative, requiring physical separation of the administration. No regulatory information exists regarding interactions with food, alcohol, supplements, or specific population-dependent interaction risks.

The mechanism of action for Tationil, which delivers Reduced L-Glutathione (G-SH), is centered on its central role as the primary regulator of the cellular redox state and an essential substrate for detoxification processes.

Redox Homeostasis and Preservation of Cellular Integrity

G-SH is the primary molecule responsible for maintaining redox balance by directly neutralizing Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) through electron donation (direct scavenging). This molecular action is continuously supported by the Glutathione Reductase (GR) enzyme, which recycles the oxidized GSSG back into active G-SH. This mechanism facilitates the prevention of chemical damage to vital cellular proteins, DNA, and lipid membranes, resulting in the preservation of cellular integrity following oxidative events.

Substrate for Systemic Toxin Clearance

G-SH acts as the obligate cofactor and substrate for the Glutathione S-Transferase (GST) enzyme family in the Phase II detoxification pathway. Through a process called nucleophilic conjugation, G-SH chemically binds to various electrophilic compounds (xenobiotics and toxic metabolites). This creates highly polar and water-soluble S-conjugates that are transported and cleared from the body via systemic biliary and renal excretion.

The administration of Tationil (Reduced L-Glutathione), a lyophilized powder, is strictly governed by specialized protocols due to its presentation as an injection. Its use is defined by three primary domains that dictate the process, dosing, and schedule, ensuring consistency with standard pharmaceutical guidelines.

Official Administration Guidelines

Usage Parameter	Administrative Parameters
Route of Administration	Must be administered via Intramuscular (IM) injection or Intravenous (IV) infusion.
Preparation	The lyophilized powder requires reconstitution (dissolving) with a specified diluent, such as Water for Injection, prior to use.
Dosing Schedule	A common supportive regimen involves 600 mg administered daily. Specialized protocols, particularly for adjunctive use, may require higher doses, such as up to 1.5 g/m^2 (grams per square meter of body surface area).

Usage Patterns and Context

Administration must occur in a supervised healthcare setting by a qualified professional due to the IM/IV route. The dosing frequency is typically once daily for a specified course duration or is cyclic and intermittent when used as an adjunct to other primary therapies, such as being given 15–30 minutes prior to chemotherapy. While explicit, widespread dose adjustments for pediatric or older adult populations are not consistently published in core labels, the g/m^2 calculation provides a method for dose adjustment based on body size.

Tationil: Recent Clinical Evidence

This section summarizes the published research exploring the use of Reduced L-Glutathione (Tationil) in specific clinical contexts. It describes the design of the studies, the outcomes that were monitored, and the areas where evidence remains limited or inconsistent.

Evidence for Use in Chronic Hepatic Injury

Short-term Randomized Controlled Trials (RCTs) have explored the adjunctive use of Glutathione alongside standard treatments for chronic liver conditions like Chronic Hepatitis B and NAFLD. Researchers monitored changes in liver enzyme levels (like ALT and AST) and indicators of liver scarring. Studies reported patterns such as the observation of shifts in measured liver enzyme levels following the intervention. Evidence related to these findings remains limited and heterogeneous, with consistency varying by the specific condition and administration route studied.

Evidence for Use in Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Glutathione was studied for its potential role in addressing outcomes related to physical discomfort caused by certain chemotherapy drugs. This research included large Phase III, Placebo-Controlled Trials. While some smaller trials reported patterns where the observed incidence of nerve toxicity was lower, a large Phase III trial reported no substantial difference in neuropathy outcomes compared to the placebo group. The consistency of the results, therefore, varies across the different types of chemotherapy that were studied.

Research Context for Supportive Use in Parkinson's Disease

Research has explored its use in Parkinson's disease (PD) through preliminary Phase I and Phase IIb pilot evaluations. These studies primarily measured changes in motor symptom severity using standardized scales. Findings were quickly followed by pilot trials that reported an unusually strong and sustained placebo response, making certainty remain low regarding a measurable symptomatic benefit. Researchers have since shifted focus towards exploring its capacity as a possible long-term disease-modifying agent.

Research Gaps and Consistency

For most studied indications, follow-up durations were limited to short-term intervention periods; longer-term effects are not fully established for liver support or nerve protection. Data for certain patient subgroups, such as those with advanced disease, are insufficient. The overall evidence base is characterized by inconsistent findings and a need for larger, definitive studies to clarify its therapeutic role.

Key Studies & References

1. Role of Glutathione in Prevention of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis

Common questions about Tationil (FAQ)

---

Q: What is Tationil used for?

Tationil is a brand name for Glutathione. In some regions, it is labeled for specific medical uses as an antioxidant or detoxification agent. Official labeling should be consulted for its approved therapeutic indications in your location.

---

Q: How is Tationil administered?

Tationil is typically administered by a healthcare professional, most often as an intravenous (IV) injection or infusion. The specific route and schedule are determined by a physician based on the patient's medical condition and regulatory guidelines.

---

Q: Are there common side effects associated with Tationil?

As with any medication, side effects are possible. Common adverse effects, especially with rapid IV administration, can include nausea, flushing, and headache. All potential risks and side effects should be discussed with a qualified healthcare provider.

---

Q: Can Tationil be purchased over the counter?

Availability varies by region. In many countries, injectable forms of Tationil (Glutathione) are prescription-only medications and must be administered in a clinical setting under medical supervision. Non-injectable forms may be available as dietary supplements.

Tationil (glutathione) in its lyophilized powder form should be stored according to the manufacturer's instructions to maintain its stability and effectiveness. Typically, this injectable powder is kept refrigerated and protected from light.

• Storage: Store the vials in their original packaging in a refrigerator at a temperature between 2^circC and 8^circC (36^circF and 46^circF). Do not allow the medication to freeze. Check the solution for any discoloration or particles before use; if present, the vial should be discarded.
• Disposal: Unused, expired, or opened vials, as well as any injection-related items like needles and syringes (sharps), must be disposed of safely. Sharps should be placed immediately into an FDA-cleared, puncture-proof sharps disposal container. Do not dispose of medication vials or sharps in household trash, down the sink, or flushed down the toilet. Follow local regulations or use a community drug take-back program for disposal of the unused medication.